Swiss National Bank Boosts Stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Swiss National Bank raised its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Rating) by 1.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 47,700 shares of the medical instruments supplier’s stock after acquiring an additional 900 shares during the quarter. Swiss National Bank’s holdings in LeMaitre Vascular were worth $2,195,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Legal & General Group Plc boosted its position in LeMaitre Vascular by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 45,769 shares of the medical instruments supplier’s stock valued at $2,084,000 after buying an additional 200 shares during the period. Arizona State Retirement System boosted its position in LeMaitre Vascular by 3.9% in the 4th quarter. Arizona State Retirement System now owns 5,577 shares of the medical instruments supplier’s stock valued at $257,000 after buying an additional 208 shares during the period. MML Investors Services LLC boosted its position in LeMaitre Vascular by 4.4% in the 3rd quarter. MML Investors Services LLC now owns 7,866 shares of the medical instruments supplier’s stock valued at $399,000 after buying an additional 334 shares during the period. Legacy Wealth Asset Management LLC boosted its position in LeMaitre Vascular by 1.9% in the 4th quarter. Legacy Wealth Asset Management LLC now owns 18,395 shares of the medical instruments supplier’s stock valued at $847,000 after buying an additional 340 shares during the period. Finally, Captrust Financial Advisors boosted its position in LeMaitre Vascular by 555.3% in the 1st quarter. Captrust Financial Advisors now owns 616 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 522 shares during the period. Hedge funds and other institutional investors own 86.85% of the company’s stock.

LeMaitre Vascular Trading Down 0.8 %

LeMaitre Vascular stock opened at $59.63 on Friday. The stock has a market cap of $1.32 billion, a P/E ratio of 63.97, a price-to-earnings-growth ratio of 5.08 and a beta of 0.99. The company has a fifty day simple moving average of $56.06 and a 200-day simple moving average of $50.21. LeMaitre Vascular, Inc. has a 12-month low of $40.82 and a 12-month high of $68.06.

LeMaitre Vascular (NASDAQ:LMAT – Get Rating) last released its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. LeMaitre Vascular had a net margin of 12.20% and a return on equity of 8.86%. The business had revenue of $47.08 million during the quarter, compared to analysts’ expectations of $43.54 million. During the same period in the previous year, the company earned $0.27 EPS. The company’s revenue for the quarter was up 19.0% on a year-over-year basis. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.2 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 1st. Investors of record on Wednesday, May 17th will be paid a dividend of $0.14 per share. The ex-dividend date is Tuesday, May 16th. This represents a $0.56 annualized dividend and a yield of 0.94%. LeMaitre Vascular’s dividend payout ratio is currently 60.22%.

Analyst Ratings Changes

Several brokerages have commented on LMAT. StockNews.com initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, May 18th. They issued a “buy” rating for the company. Barrington Research raised shares of LeMaitre Vascular from a “market perform” rating to an “outperform” rating and set a $62.00 price objective for the company in a research report on Wednesday, May 3rd. Finally, Roth Capital reaffirmed a “neutral” rating on shares of LeMaitre Vascular in a research report on Tuesday, March 7th.

Insider Buying and Selling

In related news, Director David B. Roberts sold 34,989 shares of LeMaitre Vascular stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $63.44, for a total transaction of $2,219,702.16. Following the sale, the director now directly owns 11,238 shares in the company, valued at approximately $712,938.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other LeMaitre Vascular news, insider Trent G. Kamke sold 6,414 shares of LeMaitre Vascular stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $50.94, for a total value of $326,729.16. Following the transaction, the insider now directly owns 3,791 shares in the company, valued at $193,113.54. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David B. Roberts sold 34,989 shares of LeMaitre Vascular stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $63.44, for a total transaction of $2,219,702.16. Following the completion of the transaction, the director now owns 11,238 shares in the company, valued at $712,938.72. The disclosure for this sale can be found here. Insiders have sold 153,269 shares of company stock worth $9,657,560 in the last ninety days. 12.40% of the stock is owned by corporate insiders.

About LeMaitre Vascular

(Get Rating)

LeMaitre Vascular, Inc engages in the provision of medical devices and human tissue cryopreservation services. The company focuses on the design, marketing, sales, service, and technical support of medical devices and implants for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy.